CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services


Core Curriculum on Tuberculosis, 2000

Chapter 6
Treatment of Latent TB Infection (LTBI)

Updated August 2003


  1. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982;60:555-564.
  2. Mwinga AG, Hosp M, Godfrey-Faussett P, et al. Randomized placebo controlled trial of two intermittent regimens in the prevention of HIV-related tuberculosis in Zambia. Int J Tuberc Lung Dis 1997;1(Suppl 1):S164.
  3. Halsey N, Coberly J, Desormeaux J, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
  4. Gordin F, Chaisson RE, Matts JP, et al.  Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected person: an international randomized trial. JAMA 2000;283:1445-50.
  5. Mwinga AG, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therpay in HIV infection in ZAmbia. AIDS 1998; 12:2447-57.
  6. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-5.
  7. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145:494-497.
  8. Centers for Disease Control and Prevention. Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection-United States, 2003. MMWR 2003; 52 (No. 31).


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333